Fulgent Genetics, Inc.
FLGT
$19.45
-$0.45-2.26%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.38% | -3.16% | 9.34% | 17.18% | 15.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.38% | -3.16% | 9.34% | 17.18% | 15.17% |
| Cost of Revenue | 26.06% | 10.04% | 14.40% | 7.97% | 6.36% |
| Gross Profit | -25.43% | -24.19% | 2.30% | 32.65% | 29.99% |
| SG&A Expenses | 8.91% | 10.51% | 49.65% | 16.30% | 29.27% |
| Depreciation & Amortization | 30.80% | 2.06% | 1.71% | 1.61% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.21% | 10.62% | 27.40% | 11.93% | 12.88% |
| Operating Income | -70.45% | -61.77% | -112.67% | 10.12% | -4.27% |
| Income Before Tax | -37.97% | -121.60% | -263.88% | 59.48% | -91.89% |
| Income Tax Expenses | 101.28% | -500.00% | -203.18% | 82.20% | -6.54% |
| Earnings from Continuing Operations | -54.34% | -112.40% | -282.07% | 53.55% | -111.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -36.79% | 21.41% | -23.18% | 373.91% | -21.32% |
| Net Income | -55.77% | -115.32% | -297.72% | 54.89% | -117.65% |
| EBIT | -70.45% | -61.77% | -112.67% | 10.12% | -4.27% |
| EBITDA | -89.80% | -87.53% | -183.64% | 16.55% | -7.10% |
| EPS Basic | -69.92% | -114.95% | -293.49% | 55.38% | -114.44% |
| Normalized Basic EPS | -164.16% | -103.19% | -252.98% | 15.55% | -3.27% |
| EPS Diluted | -69.92% | -114.95% | -292.59% | 55.38% | -114.00% |
| Normalized Diluted EPS | -164.16% | -103.19% | -252.98% | 15.55% | -3.27% |
| Average Basic Shares Outstanding | -8.31% | 0.16% | 1.07% | 1.09% | 1.48% |
| Average Diluted Shares Outstanding | -8.31% | 0.16% | 1.07% | 1.09% | 1.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |